Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Prevalence of Several Lifestyle Diseases
4.2.2 Rise in the Smoking and Alcohol Consumption
4.3 Market Restraints
4.3.1 Side effects of the treatment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Indication
5.1.1 Hypercholesterolemia
5.1.2 Dysbetalipoproteinemia
5.1.3 Familial Combined Hyperlipidemia
5.1.4 Others
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Online Pharmacies
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer, Inc
6.1.2 Novartis AG
6.1.3 Astrazeneca Plc
6.1.4 Merck & Co. Inc.
6.1.5 Emcure Pharmaceuticals Ltd.
6.1.6 Ranbaxy Laboratories Ltd.
6.1.7 Teva Pharmaceuticals
6.1.8 Mylan Pharmaceuticals, Inc.
6.1.9 Kowa Pharmaceuticals America, Inc.
6.1.10 Glenmark Pharmaceuticals Ltd.
6.1.11 Sun Pharmaceuticals Industries Ltd.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS